Summary
The pharmacokinetics of xamoterol, a β-adrenoceptor partial agonist under clinical evaluation for the treatment of mild to moderate heart failure, have been studied in 12 healthy male subjects. They received 14 mg i.v. and oral doses of 50 and 200 mg as a tablet and 200 mg as a solution in a 4 way cross-over design.
After i.v. dosing the elimination half-life was 7.7 h, the total body clearance was 224 ml·min−1 and the volume of distribution at steady-state (Vss) was 48 l. Sixty-two percent of the dose was recovered unchanged in urine. After oral doses, the absolute bioavailability of xamoterol was shown to be 5% irrespective of whether the dose was administered as a tablet or solution. Peak plasma concentrations occurred at about 2 h for the tablet dose and slightly earlier (1.4 h) for the solution. Peak plasma concentration, AUC and urinary recovery of unchanged drug increased in proportion to dose. The apparent elimination half-life after oral doses (16 h) was significantly longer than that observed after an intravenous dose.
Despite the low bioavailability, the degree of inter-subject variability of oral bioavailability was small probably indicating that the controlling factor is the hydrophilic nature of the molecule rather than extensive first pass metabolism or poor dissolution of xamoterol from the tablet formulation.
Similar content being viewed by others
References
Gibaldi M, Perrier D (1982) Pharmacokinetics (2nd edn). Marcel Dekker, New York
Jennings G, Bobik A, Oddie C, Restall R (1984) Cardioselectivity, kinetics, haemodynamics and metabolic effects of xamoterol. Clin Pharmacol Ther 35: 594–603
Marten TR, Bourne GR, Miles GS, Shuker B, Rankine HD, Dutka VN (1984) The metabolism of ICI 118,587, a partial agonist of β1-adrenoceptor in mice, rats, rabbits, dogs and humans. Drug Metab Dispos 12: 652–660
Nuttall A, Snow HM (1982) the cardiovascular effects of ICI 118,587: A β1-adrenoceptor partial agonist. Br J Pharmacol 77: 381–388
Rowland M, Tozer TN (1980) Clinical Pharmacokinetics: Concepts and applications. Lea and Febiger, Philadelphia
Weder HG, Schildknecht J, Kesselring P (1971) A new equilibrium dialyzing system. Am Lab 10: 15–21
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bastain, W., Boyce, M.J., Stafford, L.E. et al. Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. Eur J Clin Pharmacol 34, 469–473 (1988). https://doi.org/10.1007/BF01046704
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01046704